Editas Medicine reports Q4 2022 net loss $60.7M; advances EDIT-301 trials, sells iNK franchise to Shoreline

Editas Medicine, Inc.

2022-FY EPS reported -$3.21 revenue$19,712,000

Q4 2022 net loss $60.7M ($0.88/share) vs $41.4M ($0.61) in Q4 2021; full year net loss $220.4M ($3.21).
Cash $437.4M at Dec 31, 2022, down from $619.9M a year ago; expects to fund operations into 2025.
EDIT-301 for SCD: parallel patient dosing started in RUBY trial; on track to dose 20 patients by year-end, clinical update by mid-2023.
Entered definitive agreement to sell iNK cell franchise and license SLEEK/AsCas12a technologies to Shoreline Biosciences.
BMS opted into three additional gene editing programs and declared one new development candidate under collaboration.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Editas Medicine, Inc. reported the full year 2022 results: revenue $19.7 million, net income $220.4 million, EPS $3.21 per share.

Period: the full year 2022
Revenue: $19.7 million
Net income: $220.4 million
EPS: $3.21 per share
Result: reported results

Exact text from the filing

million, or $3.21 per share, compared to $192.5 million, or $2.85 per share, for the same period in 2021. ● Collaboration and other research and development revenues were $19.7 million for 2022, compared to $25.5 million for 2021. The $5.8 million decrease was primarily attributable decreased revenue recognized in the year ended December 31, 2022 related to the

View on SEC.gov

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Editas Medicine, Inc. reported the three months ended December 31, 2022 results: revenue $6.5 million, net income $60.7 million, EPS $0.88 per share.

Period: the three months ended December 31, 2022
Revenue: $6.5 million
Net income: $60.7 million
EPS: $0.88 per share
Result: reported results

Exact text from the filing

to net loss of $41.4 million, or $0.61 per share, for the same period in 2021. ● Collaboration and other research and development revenues decreased by $6.0 million to $6.5 million for the three months ended December 31, 2022, compared to $12.5 million for the same period in 2021. The decrease was primarily attributable to a decrease in collaboration

View on SEC.gov

Browse all earnings releases →

Editas Medicine, Inc. filing history →

Source: SEC EDGAR

accession 0001558370-23-001684

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.